GlassScriptPhysician profile
Jean Davis
NPI 1699137240
$2,414.47
in general payments reported to CMS, 2019-2025
14 companies · $700 in 2025
The $700 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.77 · 2021: $232 · 2022: $187 · 2023: $380 · 2024: $820 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.75 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $334.33 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $277.27 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $221.18 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $147.45 | 2023-2025 | Trelegy Ellipta |
| Amgen INC. | $108.43 | 2020-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $105.63 | 2023-2025 | |
| Exact Sciences Corporation | $103.53 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.19 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Seqirus USA INC | $52.48 | 2024-2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $50.49 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $29.29 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $19.49 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Eisai INC. | $15.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.